Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors

Poly(ADP-ribose)polymerase (PARP) inhibitors (PARPi) have recently been approved for the treatment of breast and ovarian tumors with defects in homologous recombination repair (HRR). Although it has been demonstrated that PARPi also sensitize HRR competent tumors to cytotoxic chemotherapies or radio...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickson, Benjamin D., Wong, Way Wua, Wilson, William R., Hay, Michael P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514732/
https://www.ncbi.nlm.nih.gov/pubmed/31010230
http://dx.doi.org/10.3390/molecules24081559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514732/
https://www.ncbi.nlm.nih.gov/pubmed/31010230
http://dx.doi.org/10.3390/molecules24081559

Ejemplares similares